Form 4: Incyte Executive Receives Substantial Equity Compensation Package

Mohamed Khairie Issa, Incyte Corporation's EVP and Head of US Oncology, was granted a significant equity award package comprising restricted stock units, performance shares, and stock options on July 15, 2025.

Summary

• Mohamed Khairie Issa, Executive Vice President and Head of US Oncology at Incyte Corp (INCY), received new equity awards on July 15, 2025.
• The awards include 8,769 restricted stock units (RSUs) which will vest 25% annually over four years and are settled one-for-one for common stock.
• An aggregate of 85,252 shares of common stock are issuable to Mr. Issa pursuant to previously reported RSUs that have not yet vested, including the July 15, 2025 grant.
• He was also granted 21,923 performance shares, each representing the right to receive up to 200% of one share of common stock.
• These performance shares can be earned based on Incyte's relative total shareholder return (TSR) compared to a fixed peer group over a three-year performance period starting January 1, 2025, and will vest on July 15, 2028, subject to continued service.
• Additionally, Mr. Issa received employee stock options to purchase 19,735 shares of common stock at an exercise price of $68.25.
• These options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years, expiring on July 14, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 7

Explanation: The equity grants are a positive sign of executive retention and alignment with shareholder interests, typical for a company of this size and industry. It represents routine compensation rather than a significant new strategic development.

Positives

• The equity grants align the executive's financial interests directly with the long-term performance and shareholder value creation of Incyte Corporation.
• The inclusion of performance shares tied to relative Total Shareholder Return (TSR) incentivizes outperformance against industry peers.
• The grants are a standard component of executive compensation, aiding in the retention and motivation of key leadership.

Negatives

• The issuance of new equity awards, particularly RSUs and performance shares, represents potential future dilution for existing shareholders upon vesting and conversion.

Risks

• The actual number of shares received from performance shares is contingent on Incyte's Total Shareholder Return (TSR) performance relative to a peer group over a three-year period, introducing performance risk.
• The value of the stock options is dependent on the future market price of Incyte's common stock exceeding the exercise price of $68.25.

Future Outlook

The performance shares are tied to Incyte's relative total shareholder return over a three-year period beginning January 1, 2025, indicating a forward-looking incentive structure for executive compensation.

Industry Context

Executive compensation packages in the pharmaceutical and biotechnology industry frequently include substantial equity components like RSUs, performance shares, and stock options. This structure is designed to attract and retain top talent, align management incentives with long-term shareholder value, and encourage innovation and strategic growth within a highly competitive sector.

Comparison to Industry Standards

• The structure of equity grants, including time-based RSUs, performance-based shares, and stock options, is a common practice in the biopharmaceutical industry, comparable to compensation strategies at companies like Amgen Inc., Gilead Sciences, Inc., or Bristol Myers Squibb Company.
• Tying performance shares to relative Total Shareholder Return (TSR) against a peer group is a widely adopted mechanism to ensure executive compensation is directly linked to market performance and competitive positioning within the sector.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and conversion of equity awards, but also increased alignment of executive interests with long-term shareholder value creation.
• Employees: Reflects standard compensation practices for senior executives, which can positively influence overall employee morale and retention strategies.

Next Steps

• Continued service of Mohamed Khairie Issa with Incyte Corporation for the vesting of RSUs and performance shares.
• Achievement of Incyte's Total Shareholder Return (TSR) targets relative to its peer group over the three-year performance period for the full earning of performance shares.

Key Dates

Recommendation

Keywords

Incyte, INCY, SEC Form 4, equity award, restricted stock units, RSUs, performance shares, stock options, executive compensation, insider transaction, Mohamed Khairie Issa, oncology